; (B) instruction on the correct method of checking a purchaser’s identification card; and (C) notifying employees of the civil penalties under this subsection. (3) If a retailer transacts sales of covered drugs at more than one physical location, for purposes of determining the number of violations by that retailer under this subsection, each individual physical location operated by that retailer shall be considered a separate retailer. (4) The Secretary shall notify retailers found to have violated section 301(eee) as soon as practicable after the Secretary discovers such violation. Such notification shall include the date and time when the failure to have a verification system as required by such section was observed to occur. (5) In this subsection, the terms covered drug and retailer have the meanings given such terms in section 506H. . (d) Applicability The amendments made by subsections (a), (b), and (c) shall apply with respect to drugs sold or offered for sale on or after the date that is one year after the date of enactment of this Act. (e) Sense of Congress regarding communication by organizations nominated by manufacturers It is the sense of Congress that organizations nominated by manufacturers of covered drugs (as defined in section 506H of the Federal Food, Drug, and Cosmetic Act, as added by subsection (c)) should make reasonable efforts to communicate to retailers (as defined in such section 506H) the requirements of such section 506H, including by making available upon request materials (which may include signage, manuals, materials, or programs) to assist with educating employees regarding such covered drugs. 3. Restrictions on distribution of bulk dextromethorphan (a) In general The Federal Food, Drug, and Cosmetic Act is amended— (1) in section 301 ( 21 U.S.C. 331 ) (as amended by section 2(a)) by adding at the end the following: (ggg) The possession, receipt, or distribution of unfinished dextromethorphan in violation of section 506I.